PMID- 35845479
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220719
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 10
IP  - 12
DP  - 2022 Jun
TI  - Efficacy and safety of combined treatment with pembrolizumab in patients with 
      locally advanced or metastatic esophageal squamous cell carcinoma in the real 
      world.
PG  - 708
LID - 10.21037/atm-22-2779 [doi]
LID - 708
AB  - BACKGROUND: Treatments for patients with advanced esophageal cancer are still 
      limited. Pembrolizumab has demonstrated antitumor activity in patients with 
      advanced esophageal cancer in previous studies. Few studies have assessed safety 
      and efficacy in routine clinical practice. We investigated the real-world 
      outcomes of pembrolizumab for patients with advanced esophageal cancer. METHODS: 
      This retrospective, observational study collected 57 advanced esophageal squamous 
      cell carcinoma (ESCC) patients from October 1, 2019 to October 1, 2021, 57 who 
      received different patterns of treatments according to the staging were 
      collected. Briefly, patients diagnosed with locally advanced and surgically 
      resectable ESCC received neoadjuvant therapy followed by surgery. For patients 
      with locally advanced, unresectable ESCC, the treatment regimen including 
      chemoradiotherapy combined with pembrolizumab was performed. Patients with 
      metastatic ESCC or those not suitable for radiotherapy received pembrolizumab 
      plus chemotherapy. Safety was assessed in all treated patients. The objective 
      response rate (ORR) was used to evaluate the efficacy. RESULTS: The ORR was 74.1% 
      (40/54) among all patients. The most common adverse events (AEs) were leukopenia 
      (36.8%, 21/57), nausea (28.1%, 16/57), and thrombocytopenia (14%, 8/57). Grade 
      III and higher AEs were observed in 9 of the 57 patients (15.8%). CONCLUSIONS: 
      For patients with advanced ESCC, combined treatment with pembrolizumab was 
      effective and safe. Multicenter studies should be carried out for further 
      confirmation.
CI  - 2022 Annals of Translational Medicine. All rights reserved.
FAU - Zhang, Pei
AU  - Zhang P
AD  - Department of Radiotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Hou, Xiaobin
AU  - Hou X
AD  - Department of Thoracic Surgery, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Cai, Boning
AU  - Cai B
AD  - Department of Radiotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Yu, Wei
AU  - Yu W
AD  - Department of Radiotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Chen, Jing
AU  - Chen J
AD  - Department of Radiotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Huang, Xiang
AU  - Huang X
AD  - Department of Radiotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Li, Ye
AU  - Li Y
AD  - Department of Radiotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Zeng, Mingyue
AU  - Zeng M
AD  - Department of Radiotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Ren, Zhipeng
AU  - Ren Z
AD  - Department of Thoracic Surgery, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Gabriel, Emmanuel
AU  - Gabriel E
AD  - Department of Surgery, Division of Surgical Oncology, Mayo Clinic, Jacksonville, 
      FL, USA.
FAU - Qu, Baolin
AU  - Qu B
AD  - Department of Radiotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Liu, Fang
AU  - Liu F
AD  - Department of Radiotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC9279766
OTO - NOTNLM
OT  - Esophageal cancer
OT  - pembrolizumab
OT  - real-world analysis
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-22-2779/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/07/19 06:00
MHDA- 2022/07/19 06:01
PMCR- 2022/06/01
CRDT- 2022/07/18 03:50
PHST- 2022/04/01 00:00 [received]
PHST- 2022/06/20 00:00 [accepted]
PHST- 2022/07/18 03:50 [entrez]
PHST- 2022/07/19 06:00 [pubmed]
PHST- 2022/07/19 06:01 [medline]
PHST- 2022/06/01 00:00 [pmc-release]
AID - atm-10-12-708 [pii]
AID - 10.21037/atm-22-2779 [doi]
PST - ppublish
SO  - Ann Transl Med. 2022 Jun;10(12):708. doi: 10.21037/atm-22-2779.